Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AURA vs PVLA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AURA Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 1–4 Matrix Metrics)

AURA Overall Winner 6-Pillar Tally: AURA 2 – 2 PVLA (2 Tie) Matrix Metrics: AURA 1 – 4 PVLA

As of Nov 16, 2026, Aura Biosciences, Inc. (AURA) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 1–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Options & Positioning). AURA carries a Unified Composite Score of 31.1/100 (SELL) at $7.21 (N/M Forward P/E, 0.0% operating margin), whereas PVLA carries 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While PVLA currently prints a higher short-term Unified Composite Score (48.2/100 HOLD vs. AURA 31.1/100 SELL), AURA captures the overall institutional head-to-head verdict (1–4 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AURA vs PVLA
AURA NASDAQ Head-to-Head Winner
Aura Biosciences, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$7.21
+1.41% 1D
Market Cap $728.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.92β · 75% Vol
Unified Composite Score
31.1 / 100 SELL
Tech 8.0 Fund 39.0 Flow 71.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 58
RSI-14: 58.3 · SMA20: $6.66 · SMA50: $6.54
PVLA NASDAQ
Palvella Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$145.03
-4.89% 1D
Market Cap $2.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.66β · 75% Vol
Unified Composite Score
48.2 / 100 HOLD
Tech 35.0 Fund 53.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 50.9 · SMA20: $148.17 · SMA50: $143.42

6-Pillar Scorecard Institutional Category Breakdown (AURA 2 – 2 PVLA)

Columns: Metric · AURA · PVLA
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale PVLA
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $728.6M $2.2B
3. Profitability & Quality AURA
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -61.7% -63.4%
4. Balance Sheet & Cash Flow PVLA
Cash Generation (TTM) -$110M -$43M
Cash Flow Margin N/A N/A
Net Cash / Leverage $26M Net Cash $193M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AURA
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 160.1% (22nd %ile) 47.9% (2nd %ile)
Put/Call OI Skew N/A 3.82x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AURA (1) vs PVLA (4)
Institutional Metric AURA PVLA Criterion Row Edge
Market Capitalization
Scale
$728.6M $2.2B Larger Scale PVLA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-61.7% -63.4% Higher ROE AURA
52-Week Range Position
Momentum
52% ($5–$10) 68% ($72–$180) Stronger Trend PVLA
Beta / 30D Volatility
Risk Regime
0.92β · 75% Vol 1.66β · 75% Vol Lower Realized Risk PVLA
Unified Institutional Score
Composite Signal
31.1 / 100 (SELL) 48.2 / 100 (HOLD) Higher Composite PVLA
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$110M ($26M Net Cash) -$43M ($193M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PVLA +2.36 pp
AURA: +18.2% · PVLA: +20.56%
3M Horizon PVLA +8.06 pp
AURA: -11.64% · PVLA: -3.58%
6M Horizon PVLA +41.54 pp
AURA: -3.48% · PVLA: +38.06%
1Y Horizon PVLA +49.78 pp
AURA: +30.38% · PVLA: +80.16%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AURA vs PVLA. Trailing 12-month operating profitability (AURA 0.0% vs PVLA 0.0%) and valuation multiples (AURA N/M vs PVLA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AURA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-61.7% · N/M
PVLA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-63.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AURA CONSOLIDATION
135d in phase · OBV DISTRIBUTION
Current IV 160.1%
IV Percentile 22nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact AURA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PVLA CONSOLIDATION
70d in phase · OBV DISTRIBUTION
Current IV 47.9%
IV Percentile 2nd %ile
Put/Call OI Skew 3.82x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact PVLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AURA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $728.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PVLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AURA vs PVLA Key Questions & Quantitative Answers

As of Nov 16, 2026, Aura Biosciences, Inc. (AURA) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 1–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Options & Positioning). AURA carries a Unified Composite Score of 31.1/100 (SELL) at $7.21 (N/M Forward P/E, 0.0% operating margin), whereas PVLA carries 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While PVLA currently prints a higher short-term Unified Composite Score (48.2/100 HOLD vs. AURA 31.1/100 SELL), AURA captures the overall institutional head-to-head verdict (1–4 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).

PVLA leads the Growth & Scale pillar: AURA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PVLA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, AURA generates N/A in USD-normalized revenue versus N/A for PVLA. In operating R&D and SG&A reinvestment, AURA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PVLA.

AURA and PVLA trade at balanced relative valuation multiples. AURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas PVLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AURA (-61.7% ROE) versus PVLA (-63.4% ROE) capital efficiency.

In options market volatility and institutional positioning, AURA carries 160.1% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.92β · 75% Vol realized risk). By comparison, PVLA carries 47.9% implied volatility (2nd %ile, Compressed (<25th %ile)), a 3.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.66β · 75% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.